Inotuzumab ozogamicin - Pfizer
Alternative Names: BESPONSA; CMC-544; InO - Pfizer; PF-05208773; PF-5208773; WAY-207294Latest Information Update: 27 May 2024
At a glance
- Originator Celltech Group; Wyeth
- Developer Pfizer
- Class Antineoplastics; Cytostatic antibiotics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action DNA damage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I/II Chronic myeloid leukaemia
- Phase I Acute biphenotypic leukaemia; Burkitt's lymphoma
- Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 26 Mar 2024 Launched for Precursor cell lymphoblastic leukaemia-lymphoma (In children, Second-line therapy or greater) in Japan (IV)
- 26 Mar 2024 Registered for Precursor cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, In children) in Japan (IV)
- 06 Mar 2024 Launched for Precursor B-cell lymphoblastic leukaemia-lymphoma (In adolescents, In children, In infants, Second-line therapy or greater) in USA (IV)